Start offering CellTolerance® to your patients today.
Up to 12% of the US population is reported to have IBS1. Only half of patients with IBS receive a definitive diagnosis after seeing a physician. With CellTolerance® you can offer a complete program towards a healthier life by addressing food intolerances.
Up to 12% of the US population is reported to have IBS1. According to our YouGov survey, many struggle for years without finding a definite resolution.
At the heart of this program is the revolutionary CellTolerance Test, which helps you identify and manage specific intolerances.
96% of patients improved their symptoms with cell-response guided diet2 and patients reported better improvement than with Low-FODMAP Diet3.
Stand out by providing unique, evidence-based care that addresses a significant unmet patient need.
Contact us
Get in touch with the CellTolerance® team.
References
- CheyWD, KurlanderJ, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015 Mar3;313(9):949-58. doi:10.1001/jama.2015.0954
- Fritscher-RavensA, PflaumT, Mösingeret al. Many Patients With Irritable Bowel Syndrome Have Atypical Food AllergiesNot Associated With Immunoglobulin E. Gastroenterology. 2019Jul;157(1):109-118.
- Fritscher-RavensA, Exclusion of atypical food allergens detected by confocal endomicroscopy issuperior to low fodmap diet in patients with food-sensitive IBS. AGAABSTRACTS|VOLUME158,ISSUE6,SUPPLEMENT1,S-135, MAY 01, 2020